RAJESH BEHL
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
- Where
- BERKELEY, CA
- NPI
- 1104844174
- Received
- $583,960 in 777 records, 2019 to 2025 ($583,925 general, $35 research)
- As principal investigator
- $548,941 of research payments to others in 79 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 342 | $164,983 |
| 2024 | General payment | 61 | $56,386 |
| 2023 | General payment | 58 | $59,789 |
| 2023 | Research payment | 1 | $35 |
| 2022 | General payment | 123 | $153,919 |
| 2021 | General payment | 66 | $79,546 |
| 2020 | General payment | 26 | $19,881 |
| 2019 | General payment | 100 | $49,418 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 74 | $206,815 |
| Honoraria | 45 | $155,651 |
| Consulting Fee | 62 | $144,683 |
| Travel and Lodging | 150 | $57,882 |
| Food and Beverage | 426 | $18,451 |
| Education | 19 | $441 |
| Research payment | 1 | $35 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-24 | Syndax Pharmaceuticals, Inc. | $3,127 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REVUFORJ Drug, HEMATOLOGY-ONCOLOGY | 2025 | |
| 2025-12-22 | Legend Biotech USA Inc. | $24 | Food and Beverage | In-kind items and services | CARVYKTI Biological, Oncology | 2025 | |
| 2025-12-21 | Syndax Pharmaceuticals, Inc. | $21 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-12-18 | ABBVIE INC. | $3,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | 2025 | |
| 2025-12-18 | ABBVIE INC. | $3,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | EPKINLY Drug, ONCOLOGY | 2025 | |
| 2025-12-18 | Syndax Pharmaceuticals, Inc. | $1,042 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REVUFORJ Drug, HEMATOLOGY-ONCOLOGY | 2025 | |
| 2025-12-18 | E.R. Squibb & Sons, L.L.C. | $30 | Food and Beverage | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2025 | |
| 2025-12-18 | E.R. Squibb & Sons, L.L.C. | $1 | Food and Beverage | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2025 | |
| 2025-12-17 | BeOne Medicines USA, Inc. | $24 | Food and Beverage | In-kind items and services | BRUKINSA Drug, Oncology | 2025 | |
| 2025-12-11 | ABBVIE INC. | $164 | Travel and Lodging | In-kind items and services | EPKINLY Drug, ONCOLOGY | 2025 | |
| 2025-12-11 | ABBVIE INC. | $41 | Food and Beverage | In-kind items and services | EPKINLY Drug, ONCOLOGY | 2025 | |
| 2025-12-11 | AstraZeneca Pharmaceuticals LP | $28 | Food and Beverage | In-kind items and services | TAGRISSO Drug, Oncology | 2025 | |
| 2025-12-10 | Karyopharm Therapeutics Inc. | $1,550 | Honoraria | Cash or cash equivalent | XPOVIO Drug, Oncology | 2025 | |
| 2025-12-09 | Syndax Pharmaceuticals, Inc. | $147 | Food and Beverage | In-kind items and services | REVUFORJ Drug, HEMATOLOGY-ONCOLOGY | 2025 | |
| 2025-12-08 | Kite Pharma, Inc. | $26 | Food and Beverage | In-kind items and services | Yescarta Drug, CELLT | 2025 | |
| 2025-12-04 | ABBVIE INC. | $251 | Travel and Lodging | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | 2025 | |
| 2025-12-04 | ABBVIE INC. | $124 | Food and Beverage | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | 2025 | |
| 2025-12-04 | E.R. Squibb & Sons, L.L.C. | $32 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-12-03 | PFIZER INC. | $34 | Food and Beverage | In-kind items and services | IBRANCE Drug, ONCOLOGY | 2025 | |
| 2025-12-03 | Takeda Pharmaceuticals U.S.A., Inc. | $21 | Food and Beverage | In-kind items and services | ICLUSIG Drug, ONCOLOGY | 2025 | |
| 2025-12-03 | Takeda Pharmaceuticals U.S.A., Inc. | $1 | Food and Beverage | In-kind items and services | NINLARO Drug, ONCOLOGY | 2025 | |
| 2025-12-02 | JAZZ PHARMACEUTICALS INC. | $37 | Food and Beverage | In-kind items and services | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | 2025 | |
| 2025-12-01 | Agios Pharmaceuticals, Inc. | $23 | Food and Beverage | In-kind items and services | PYRUKYND Drug, Genetically Defined Disease | 2025 | |
| 2025-11-26 | ABBVIE INC. | $0 | Food and Beverage | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | 2025 | |
| 2025-11-25 | ABBVIE INC. | $25 | Food and Beverage | In-kind items and services | EPKINLY Drug, ONCOLOGY | 2025 | |
| 2025-11-20 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | 2025 | |
| 2025-11-19 | GENZYME CORPORATION | $25 | Food and Beverage | In-kind items and services | SARCLISA Biological, Oncology | 2025 | |
| 2025-11-18 | ARRAY BIOPHARMA INC | $24 | Food and Beverage | In-kind items and services | BRAFTOVI Drug, ONCOLOGY | 2025 | |
| 2025-11-17 | Incyte Corporation | $24 | Food and Beverage | Cash or cash equivalent | ZYNYZ Drug, Oncology | 2025 | |
| 2025-11-13 | Merck Sharp & Dohme LLC | $31 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-11-12 | Janssen Biotech, Inc. | $53 | Food and Beverage | In-kind items and services | DARZALEX Biological, Oncology | 2025 | |
| 2025-11-11 | Takeda Pharmaceuticals U.S.A., Inc. | $21 | Food and Beverage | In-kind items and services | ICLUSIG Drug, ONCOLOGY | 2025 | |
| 2025-11-11 | PFIZER INC. | $20 | Food and Beverage | In-kind items and services | XTANDI Drug, ONCOLOGY | 2025 | |
| 2025-11-11 | Takeda Pharmaceuticals U.S.A., Inc. | $1 | Food and Beverage | In-kind items and services | NINLARO Drug, ONCOLOGY | 2025 | |
| 2025-11-08 | Genmab U.S., Inc. | $1,950 | Consulting Fee | Cash or cash equivalent | Epkinly Drug, Oncology | 2025 | |
| 2025-11-08 | Genmab U.S., Inc. | $102 | Food and Beverage | In-kind items and services | Epkinly Drug, Oncology | 2025 | |
| 2025-11-08 | Genmab U.S., Inc. | $41 | Food and Beverage | In-kind items and services | Epkinly Drug, Oncology | 2025 | |
| 2025-11-08 | Genmab U.S., Inc. | $21 | Travel and Lodging | Cash or cash equivalent | Epkinly Drug, Oncology | 2025 | |
| 2025-11-06 | Merck Sharp & Dohme LLC | $30 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-11-05 | Janssen Biotech, Inc. | $226 | Travel and Lodging | Cash or cash equivalent | RYBREVANT Drug, Oncology | 2025 | |
| 2025-11-05 | GlaxoSmithKline, LLC. | $33 | Food and Beverage | In-kind items and services | JEMPERLI Biological, ONCOLOGY | 2025 | |
| 2025-11-05 | E.R. Squibb & Sons, L.L.C. | $32 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-11-05 | Invivyd Inc | $20 | Food and Beverage | In-kind items and services | PEMGARDA Biological, INFECTIOUS DISEASE | 2025 | |
| 2025-11-04 | E.R. Squibb & Sons, L.L.C. | $21 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-11-03 | SOBI, INC | $36 | Food and Beverage | In-kind items and services | Vonjo Drug, Hematology/Oncology | 2025 | |
| 2025-10-30 | Karyopharm Therapeutics Inc. | $3,875 | Honoraria | Cash or cash equivalent | XPOVIO Drug, Oncology | 2025 | |
| 2025-10-30 | Karyopharm Therapeutics Inc. | $122 | Food and Beverage | In-kind items and services | XPOVIO Drug, Oncology | 2025 | |
| 2025-10-30 | PFIZER INC. | $35 | Food and Beverage | In-kind items and services | PADCEV Biological, ONCOLOGY | 2025 | |
| 2025-10-29 | Incyte Corporation | $2,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-10-29 | Genmab U.S., Inc. | $600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Epkinly Drug, Oncology | 2025 | |
| 2025-10-29 | Takeda Pharmaceuticals U.S.A., Inc. | $30 | Food and Beverage | In-kind items and services | ICLUSIG Drug, ONCOLOGY | 2025 | |
| 2025-10-29 | Takeda Pharmaceuticals U.S.A., Inc. | $1 | Food and Beverage | In-kind items and services | NINLARO Drug, ONCOLOGY | 2025 | |
| 2025-10-27 | Merck Sharp & Dohme LLC | $25 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-10-27 | Tempus AI, Inc | $18 | Food and Beverage | In-kind items and services | XT CDX Device, ONCOLOGY | 2025 | |
| 2025-10-23 | Janssen Biotech, Inc. | $2,860 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RYBREVANT Drug, Oncology | 2025 | |
| 2025-10-23 | Incyte Corporation | $124 | Food and Beverage | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-10-23 | Janssen Biotech, Inc. | $36 | Food and Beverage | In-kind items and services | ERLEADA Drug, Oncology | 2025 | |
| 2025-10-23 | AstraZeneca Pharmaceuticals LP | $21 | Food and Beverage | In-kind items and services | ENHERTU Biological, Oncology | 2025 | |
| 2025-10-23 | Incyte Corporation | $13 | Travel and Lodging | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-10-22 | Janssen Biotech, Inc. | $108 | Food and Beverage | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-10-21 | ARRAY BIOPHARMA INC | $35 | Food and Beverage | In-kind items and services | LORBRENA Drug, ONCOLOGY | 2025 | |
| 2025-10-20 | Merck Sharp & Dohme LLC | $30 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-10-17 | Janssen Biotech, Inc. | $880 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RYBREVANT Drug, Oncology | 2025 | |
| 2025-10-16 | Janssen Biotech, Inc. | $3,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RYBREVANT Drug, Oncology | 2025 | |
| 2025-10-16 | Janssen Biotech, Inc. | $234 | Travel and Lodging | Cash or cash equivalent | RYBREVANT Drug, Oncology | 2025 | |
| 2025-10-16 | Ipsen Biopharmaceuticals, Inc | $34 | Food and Beverage | In-kind items and services | Onivyde Drug, Oncology | 2025 | |
| 2025-10-14 | Janssen Biotech, Inc. | $47 | Food and Beverage | In-kind items and services | DARZALEX Drug, Oncology | 2025 | |
| 2025-10-10 | ABBVIE INC. | $2,100 | Consulting Fee | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | 2025 | |
| 2025-10-10 | Celgene Corporation | $31 | Food and Beverage | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2025 | |
| 2025-10-10 | Celgene Corporation | $0 | Food and Beverage | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2025 | |
| 2025-10-09 | Janssen Biotech, Inc. | $115 | Food and Beverage | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-10-08 | EMD Serono, Inc. | $21 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-10-07 | Gilead Sciences, Inc. | $24 | Food and Beverage | In-kind items and services | Trodelvy Drug, ONC | 2025 | |
| 2025-10-06 | E.R. Squibb & Sons, L.L.C. | $18 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-10-01 | ABBVIE INC. | $3,600 | Consulting Fee | Cash or cash equivalent | EPKINLY Drug, ONCOLOGY | 2025 | |
| 2025-10-01 | ABBVIE INC. | $778 | Travel and Lodging | In-kind items and services | EPKINLY Drug, ONCOLOGY | 2025 | |
| 2025-10-01 | ABBVIE INC. | $275 | Travel and Lodging | In-kind items and services | EPKINLY Drug, ONCOLOGY | 2025 | |
| 2025-10-01 | ABBVIE INC. | $250 | Travel and Lodging | In-kind items and services | EPKINLY Drug, ONCOLOGY | 2025 | |
| 2025-10-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | $23 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-29 | Eisai Inc. | $23 | Food and Beverage | In-kind items and services | Lenvima Drug, Oncology | 2025 | |
| 2025-09-25 | Deciphera Pharmaceuticals Inc. | $21 | Food and Beverage | In-kind items and services | QINLOCK Drug, ONCOLOGY | 2025 | |
| 2025-09-24 | Incyte Corporation | $2,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-09-22 | GENZYME CORPORATION | $38 | Food and Beverage | In-kind items and services | WAYRILZ Drug, Immunology | 2025 | |
| 2025-09-18 | ABBVIE INC. | $3,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | 2025 | |
| 2025-09-18 | Incyte Corporation | $197 | Travel and Lodging | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-09-18 | Incyte Corporation | $73 | Food and Beverage | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-09-17 | Kite Pharma, Inc. | $29 | Food and Beverage | In-kind items and services | Yescarta Drug, CELLT | 2025 | |
| 2025-09-17 | BeOne Medicines USA, Inc. | $24 | Food and Beverage | In-kind items and services | BRUKINSA Drug, Oncology | 2025 | |
| 2025-09-15 | Genmab U.S., Inc. | $3,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Epkinly Drug, Oncology | 2025 | |
| 2025-09-15 | Fennec Pharmaceuticals, Inc. | $25 | Food and Beverage | In-kind items and services | Fyarro Drug, Cancer | 2025 | |
| 2025-09-15 | AstraZeneca Pharmaceuticals LP | $23 | Food and Beverage | In-kind items and services | IMFINZI Biological, Oncology | 2025 | |
| 2025-09-12 | Takeda Pharmaceuticals U.S.A., Inc. | $22 | Food and Beverage | In-kind items and services | FRUZAQLA Drug, ONCOLOGY | 2025 | |
| 2025-09-11 | E.R. Squibb & Sons, L.L.C. | $575 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-09-11 | Celgene Corporation | $22 | Food and Beverage | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2025 | |
| 2025-09-10 | ABBVIE INC. | $125 | Food and Beverage | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | 2025 | |
| 2025-09-10 | Takeda Pharmaceuticals U.S.A., Inc. | $30 | Food and Beverage | In-kind items and services | ICLUSIG Drug, ONCOLOGY | 2025 | |
| 2025-09-10 | ABBVIE INC. | $29 | Travel and Lodging | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | 2025 | |
| 2025-09-10 | Alexion Pharmaceuticals, Inc. | $27 | Food and Beverage | In-kind items and services | ULTOMIRIS Biological, Rare Disease | 2025 | |
| 2025-09-10 | Takeda Pharmaceuticals U.S.A., Inc. | $1 | Food and Beverage | In-kind items and services | NINLARO Drug, ONCOLOGY | 2025 | |
| 2025-09-09 | Genmab U.S., Inc. | $84 | Travel and Lodging | Cash or cash equivalent | Epkinly Drug, Oncology | 2025 | |
| 2025-09-08 | E.R. Squibb & Sons, L.L.C. | $20 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-09-05 | ABBVIE INC. | $115 | Food and Beverage | In-kind items and services | EPKINLY Drug, ONCOLOGY | 2025 | |
| 2025-09-05 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | EPKINLY Drug, ONCOLOGY | 2025 | |
| 2025-09-04 | Janssen Biotech, Inc. | $33 | Food and Beverage | In-kind items and services | DARZALEX Biological, Oncology | 2025 | |
| 2025-09-03 | Tempus AI, Inc | $15 | Food and Beverage | In-kind items and services | XT CDX Device, ONCOLOGY | 2025 | |
| 2025-08-29 | Invivyd Inc | $2,817 | Consulting Fee | Cash or cash equivalent | PEMGARDA Biological, INFECTIOUS DISEASE | 2025 | |
| 2025-08-27 | E.R. Squibb & Sons, L.L.C. | $22 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-08-27 | ADC THERAPEUTICS AMERICA, INC. | $21 | Food and Beverage | Cash or cash equivalent | ZYNLONTA Drug, ONCOLOGY | 2025 | |
| 2025-08-26 | JAZZ PHARMACEUTICALS INC. | $34 | Food and Beverage | In-kind items and services | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | 2025 | |
| 2025-08-25 | Celgene Corporation | $25 | Food and Beverage | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2025 | |
| 2025-08-22 | E.R. Squibb & Sons, L.L.C. | $4,025 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-08-22 | ABBVIE INC. | $1,200 | Consulting Fee | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | 2025 | |
| 2025-08-22 | AstraZeneca Pharmaceuticals LP | $27 | Food and Beverage | In-kind items and services | IMFINZI Biological, Oncology | 2025 | |
| 2025-08-21 | Janssen Biotech, Inc. | $880 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RYBREVANT Drug, Oncology | 2025 | |
| 2025-08-21 | Takeda Pharmaceuticals U.S.A., Inc. | $26 | Food and Beverage | In-kind items and services | ICLUSIG Drug, ONCOLOGY | 2025 | |
| 2025-08-20 | Syndax Pharmaceuticals, Inc. | $21 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-19 | ARRAY BIOPHARMA INC | $31 | Food and Beverage | In-kind items and services | BRAFTOVI Drug, ONCOLOGY | 2025 | |
| 2025-08-18 | Janssen Biotech, Inc. | $32 | Food and Beverage | In-kind items and services | CARVYKTI Drug, Oncology | 2025 | |
| 2025-08-18 | Janssen Pharmaceuticals, Inc | $15 | Education | In-kind items and services | 2025 | ||
| 2025-08-18 | Janssen Pharmaceuticals, Inc | $8 | Education | In-kind items and services | 2025 | ||
| 2025-08-15 | Janssen Biotech, Inc. | $3,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RYBREVANT Drug, Oncology | 2025 | |
| 2025-08-15 | Janssen Biotech, Inc. | $902 | Travel and Lodging | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-08-15 | Janssen Biotech, Inc. | $49 | Travel and Lodging | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-08-14 | Janssen Biotech, Inc. | $368 | Travel and Lodging | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-08-14 | Incyte Corporation | $24 | Food and Beverage | Cash or cash equivalent | MONJUVI Drug, Oncology | 2025 | |
| 2025-08-13 | Janssen Biotech, Inc. | $121 | Food and Beverage | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-08-12 | Incyte Corporation | $27 | Food and Beverage | Cash or cash equivalent | JAKAFI Drug, Hematology/Oncology | 2025 | |
| 2025-08-11 | Janssen Biotech, Inc. | $5 | Travel and Lodging | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-08-08 | Janssen Biotech, Inc. | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RYBREVANT Drug, Oncology | 2025 | |
| 2025-08-05 | AstraZeneca Pharmaceuticals LP | $25 | Food and Beverage | In-kind items and services | LYNPARZA Drug, Oncology | 2025 | |
| 2025-08-04 | Daiichi Sankyo Inc. | $28 | Food and Beverage | In-kind items and services | DATROWAY Drug, ONCOLOGY | 2025 | |
| 2025-08-01 | Genmab U.S., Inc. | $3,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Epkinly Drug, Oncology | 2025 | |
| 2025-08-01 | Janssen Biotech, Inc. | $2,860 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RYBREVANT Drug, Oncology | 2025 | |
| 2025-07-31 | Genmab U.S., Inc. | $124 | Food and Beverage | In-kind items and services | Epkinly Drug, Oncology | 2025 | |
| 2025-07-31 | Iovance Biotherapeutics, Inc. | $22 | Food and Beverage | Cash or cash equivalent | Amtagvi Drug, Oncology | 2025 | |
| 2025-07-30 | Janssen Biotech, Inc. | $121 | Food and Beverage | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-07-30 | Merck Sharp & Dohme LLC | $26 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-07-29 | Janssen Biotech, Inc. | $2,860 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RYBREVANT Drug, Oncology | 2025 | |
| 2025-07-29 | Novartis Pharmaceuticals Corporation | $34 | Food and Beverage | In-kind items and services | LUTATHERA Drug, Oncology | 2025 | |
| 2025-07-28 | AstraZeneca Pharmaceuticals LP | $31 | Food and Beverage | In-kind items and services | TAGRISSO Drug, Oncology | 2025 | |
| 2025-07-25 | Takeda Pharmaceuticals U.S.A., Inc. | $20 | Food and Beverage | In-kind items and services | ICLUSIG Drug, ONCOLOGY | 2025 | |
| 2025-07-25 | Takeda Pharmaceuticals U.S.A., Inc. | $4 | Food and Beverage | In-kind items and services | ICLUSIG Drug, ONCOLOGY | 2025 | |
| 2025-07-25 | Takeda Pharmaceuticals U.S.A., Inc. | $1 | Food and Beverage | In-kind items and services | NINLARO Drug, ONCOLOGY | 2025 | |
| 2025-07-24 | ABBVIE INC. | $3,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | 2025 | |
| 2025-07-24 | Janssen Biotech, Inc. | $110 | Food and Beverage | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-07-24 | Merck Sharp & Dohme LLC | $30 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-07-23 | Karyopharm Therapeutics Inc. | $96 | Food and Beverage | In-kind items and services | XPOVIO Drug, Oncology | 2025 | |
| 2025-07-22 | ARRAY BIOPHARMA INC | $24 | Food and Beverage | In-kind items and services | LORBRENA Drug, ONCOLOGY | 2025 | |
| 2025-07-22 | AstraZeneca Pharmaceuticals LP | $22 | Food and Beverage | In-kind items and services | IMFINZI Biological, Oncology | 2025 | |
| 2025-07-17 | Incyte Corporation | $5,775 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-07-16 | Novartis Pharmaceuticals Corporation | $4,200 | Consulting Fee | Cash or cash equivalent | KYMRIAH Drug, Oncology | 2025 | |
| 2025-07-16 | ARRAY BIOPHARMA INC | $25 | Food and Beverage | In-kind items and services | LORBRENA Drug, ONCOLOGY | 2025 | |
| 2025-07-16 | PFIZER INC. | $19 | Food and Beverage | In-kind items and services | XTANDI Drug, ONCOLOGY | 2025 | |
| 2025-07-14 | ABBVIE INC. | $149 | Food and Beverage | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | 2025 | |
| 2025-07-14 | ABBVIE INC. | $22 | Travel and Lodging | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | 2025 | |
| 2025-07-14 | ABBVIE INC. | $19 | Travel and Lodging | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | 2025 | |
| 2025-07-12 | Janssen Biotech, Inc. | $115 | Travel and Lodging | Cash or cash equivalent | RYBREVANT Drug, Oncology | 2025 | |
| 2025-07-12 | Janssen Biotech, Inc. | $98 | Travel and Lodging | Cash or cash equivalent | RYBREVANT Drug, Oncology | 2025 | |
| 2025-07-12 | Janssen Biotech, Inc. | $47 | Food and Beverage | Cash or cash equivalent | RYBREVANT Drug, Oncology | 2025 | |
| 2025-07-10 | ABBVIE INC. | $600 | Consulting Fee | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | 2025 | |
| 2025-07-10 | Merck Sharp & Dohme LLC | $27 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-07-09 | Iovance Biotherapeutics, Inc. | $28 | Food and Beverage | Cash or cash equivalent | Amtagvi Drug, Oncology | 2025 | |
| 2025-07-09 | Incyte Corporation | $13 | Food and Beverage | Cash or cash equivalent | MONJUVI Drug, Oncology | 2025 | |
| 2025-07-08 | Rigel Pharmaceuticals, Inc. | $22 | Food and Beverage | Cash or cash equivalent | TAVALISSE Drug, Hematology | 2025 | |
| 2025-07-07 | E.R. Squibb & Sons, L.L.C. | $30 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-07-03 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | 2025 | |
| 2025-07-02 | Janssen Biotech, Inc. | $3,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RYBREVANT Drug, Oncology | 2025 | |
| 2025-07-02 | Janssen Biotech, Inc. | $1,650 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RYBREVANT Drug, Oncology | 2025 | |
| 2025-07-02 | Janssen Biotech, Inc. | $880 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RYBREVANT Drug, Oncology | 2025 | |
| 2025-07-02 | Merck Sharp & Dohme LLC | $19 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-07-01 | Genmab U.S., Inc. | $26 | Food and Beverage | In-kind items and services | Epkinly Drug, Oncology | 2025 | |
| 2025-06-30 | Celgene Corporation | $30 | Food and Beverage | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2025 | |
| 2025-06-30 | Celgene Corporation | $0 | Food and Beverage | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2025 | |
| 2025-06-28 | Incyte Corporation | $1,371 | Travel and Lodging | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-06-28 | Incyte Corporation | $303 | Travel and Lodging | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-06-28 | Incyte Corporation | $108 | Travel and Lodging | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-06-28 | Incyte Corporation | $60 | Food and Beverage | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-06-28 | Incyte Corporation | $59 | Food and Beverage | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-06-28 | Incyte Corporation | $29 | Food and Beverage | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-06-28 | Incyte Corporation | $29 | Food and Beverage | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-06-27 | Incyte Corporation | $12 | Food and Beverage | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-06-26 | Janssen Biotech, Inc. | $139 | Food and Beverage | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-06-26 | Integra LifeSciences Corporation | $44 | Food and Beverage | In-kind items and services | OMNIGRAFT Device, Recon-Skin and Wound | 2025 | |
| 2025-06-26 | Janssen Biotech, Inc. | $26 | Food and Beverage | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-06-25 | Janssen Biotech, Inc. | $33 | Food and Beverage | In-kind items and services | DARZALEX Biological, Oncology | 2025 | |
| 2025-06-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | $26 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-24 | Janssen Biotech, Inc. | $707 | Travel and Lodging | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-06-23 | SpringWorks Therapeutics, Inc. | $27 | Food and Beverage | In-kind items and services | GOMEKLI Drug, NEUROFIBROMATOSIS TYPE 1-ASSOCIATED PLEXIFORM NEUROFIBROMAS | 2025 | |
| 2025-06-23 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | IMBRUVICA Drug, ONCOLOGY | 2025 | |
| 2025-06-19 | Eisai Inc. | $24 | Food and Beverage | In-kind items and services | Lenvima Drug, Oncology | 2025 | |
| 2025-06-19 | Lilly USA, LLC | $23 | Food and Beverage | In-kind items and services | VERZENIO Drug, Oncology | 2025 | |
| 2025-06-18 | GlaxoSmithKline, LLC. | $31 | Food and Beverage | In-kind items and services | JEMPERLI Biological, ONCOLOGY | 2025 | |
| 2025-06-18 | AstraZeneca Pharmaceuticals LP | $23 | Education | In-kind items and services | 2025 | ||
| 2025-06-17 | Karyopharm Therapeutics Inc. | $3,875 | Honoraria | Cash or cash equivalent | XPOVIO Drug, Oncology | 2025 | |
| 2025-06-17 | Novartis Pharmaceuticals Corporation | $2,100 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-06-17 | Karyopharm Therapeutics Inc. | $218 | Travel and Lodging | Cash or cash equivalent | XPOVIO Drug, Oncology | 2025 | |
| 2025-06-17 | Karyopharm Therapeutics Inc. | $119 | Food and Beverage | In-kind items and services | XPOVIO Drug, Oncology | 2025 | |
| 2025-06-13 | Genmab U.S., Inc. | $4,160 | Consulting Fee | Cash or cash equivalent | Epkinly Drug, Oncology | 2025 | |
| 2025-06-12 | Celgene Corporation | $26 | Food and Beverage | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2025 | |
| 2025-06-10 | Merck Sharp & Dohme LLC | $34 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 |
The latest 200 records of 777.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-09-25 | Incyte Corporation | Sutter Santa Rosa Regional Hospital | $3,450 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxo | 2025 |
| 2025-05-28 | Celgene Corporation | CPMC-R.K. DAVIES MEDICAL CENTER | $1,875 | Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Regist | 2025 |
| 2025-04-03 | ABBVIE INC. | Sutter Santa Rosa Regional Hospital | $15,053 | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C | 2025 |
| 2025-03-07 | ABBVIE INC. | Sutter Santa Rosa Regional Hospital | $6,907 | M20-621 - A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combinatio | 2025 |
| 2025-03-06 | Incyte Corporation | Sutter Santa Rosa Regional Hospital | $431 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxo | 2025 |
| 2025-02-06 | ABBVIE INC. | Sutter Santa Rosa Regional Hospital | $18,044 | M20-621 - A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combinatio | 2025 |
| 2025-01-01 | Novartis Pharmaceuticals Corporation | ALTA BATES SUMMIT MEDICAL CENTER | $78,235 | A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase | 2025 |
| 2024-12-30 | ABBVIE INC. | CPMC-R.K. DAVIES MEDICAL CENTER | $5,821 | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C | 2024 |
| 2024-12-05 | ABBVIE INC. | CPMC-R.K. DAVIES MEDICAL CENTER | $23,765 | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C | 2024 |
| 2024-11-07 | ABBVIE INC. | CPMC-R.K. DAVIES MEDICAL CENTER | $5,665 | A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With R-CHOP Compar | 2024 |
| 2024-10-03 | ABBVIE INC. | CPMC-R.K. DAVIES MEDICAL CENTER | $12,771 | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C | 2024 |
| 2024-09-11 | Celgene Corporation | Cpmc - Mission Bernal Campus | $1,500 | Celgene Connect Myeloid Disease Registry | 2024 |
| 2024-09-05 | E.R. Squibb & Sons, L.L.C. | ALTA BATES SUMMIT MEDICAL CENTER | $375 | Connect MM The Multiple Myeloma Disease Registry | 2024 |
| 2024-09-04 | ABBVIE INC. | CPMC-R.K. DAVIES MEDICAL CENTER | $17,267 | Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participa | 2024 |
| 2024-09-04 | ABBVIE INC. | CPMC-R.K. DAVIES MEDICAL CENTER | $22,011 | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C | 2024 |
| 2024-08-02 | ABBVIE INC. | CPMC-R.K. DAVIES MEDICAL CENTER | $7,227 | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C | 2024 |
| 2024-07-05 | ABBVIE INC. | CPMC-R.K. DAVIES MEDICAL CENTER | $32,961 | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C | 2024 |
| 2024-06-06 | ABBVIE INC. | Sutter Santa Rosa Regional Hospital | $17,267 | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse | 2024 |
| 2024-05-28 | Novartis Pharmaceuticals Corporation | ALTA BATES SUMMIT MEDICAL CENTER | $135,760 | A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase | 2024 |
| 2024-05-15 | Celgene Corporation | Cpmc - Mission Bernal Campus | $375 | The purpose of the Connect Myeloid disease registry is to provide unique insights into treatment decisions and treatment | 2024 |
| 2024-03-07 | Incyte Corporation | Cpmc - Mission Bernal Campus | $3,885 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxo | 2024 |
| 2024-03-07 | ABBVIE INC. | CPMC-R.K. DAVIES MEDICAL CENTER | $17,267 | A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with | 2024 |
| 2024-01-31 | Celgene Corporation | Cpmc - Mission Bernal Campus | $375 | The purpose of the Connect Myeloid disease registry is to provide unique insights into treatment decisions and treatment | 2024 |
| 2024-01-18 | Incyte Corporation | Cpmc - Mission Bernal Campus | $3,450 | A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kd Inhibitor Parsaclisib Plus Ruxolitinib in Participants | 2024 |
| 2023-11-10 | Celgene Corporation | Cpmc Van Ness Campus | $546 | A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single | 2023 |
| 2023-08-09 | Incyte Corporation | SUTTER SANTA ROSA REGIONAL HOSPITAL | $500 | A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kd Inhibitor Parsaclisib Plus Ruxolitinib in Participants | 2023 |
| 2023-06-07 | Celgene Corporation | ALTA BATES SUMMIT MEDICAL CENTER | $375 | Connect MM- The Multiple Myeloma Disease Registry | 2023 |
| 2023-05-23 | Celgene Corporation | ALTA BATES SUMMIT MEDICAL CENTER | $2,250 | A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single | 2023 |
| 2023-03-29 | Incyte Corporation | SUTTER SANTA ROSA REGIONAL HOSPITAL | $1,350 | A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kd Inhibitor Parsaclisib Plus Ruxolitinib in Participants | 2023 |
| 2023-03-23 | Incyte Corporation | SUTTER SANTA ROSA REGIONAL HOSPITAL | $1,350 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxo | 2023 |
| 2023-01-18 | Celgene Corporation | Cpmc Van Ness Campus | $2,625 | Connect MDS/AML - Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (A | 2023 |
| 2022-12-28 | Incyte Corporation | Cpmc-R.K. Davies Medical Center | $1,500 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxo | 2022 |
| 2022-11-03 | Incyte Corporation | Cpmc-R.K. Davies Medical Center | $18,750 | A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kd Inhibitor Parsaclisib Plus Ruxolitinib in Participants | 2022 |
| 2022-10-20 | Incyte Corporation | Cpmc-R.K. Davies Medical Center | $1,550 | A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kd Inhibitor Parsaclisib Plus Ruxolitinib in Participants | 2022 |
| 2022-09-15 | Incyte Corporation | Cpmc-R.K. Davies Medical Center | $750 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxo | 2022 |
| 2022-09-13 | Celgene Corporation | ALTA BATES SUMMIT MEDICAL CENTER | $375 | Connect MM- The Multiple Myeloma Disease Registry | 2022 |
| 2022-08-30 | Incyte Corporation | Cpmc-R.K. Davies Medical Center | $18,750 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxo | 2022 |
| 2022-07-27 | Celgene Corporation | Cpmc Van Ness Campus | $2,250 | Connect MDS/AML - Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (A | 2022 |
| 2022-01-21 | Celgene Corporation | Cpmc Van Ness Campus | $910 | A Phase 3B Randomized Study of Lenalidomide (CC-50 | 2022 |
| 2022-01-20 | E.R. Squibb & Sons, L.L.C. | Cpmc-R.K. Davies Medical Center | $19,170 | A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previo | 2022 |
| 2021-11-23 | Celgene Corporation | ALTA BATES SUMMIT MEDICAL CENTER | $1,875 | Connect MM- The Multiple Myeloma Disease Registry | 2021 |
| 2021-08-04 | Celgene Corporation | Cpmc Van Ness Campus | $3,125 | Connect MDS/AML | 2021 |
| 2021-02-12 | Celgene Corporation | ALTA BATES SUMMIT MEDICAL CENTER | $3,000 | A Phase 3B Randomized Study of Lenalidomide (CC-50 | 2021 |
| 2020-12-23 | Incyte Corporation | St. Lukes Hospital | $4,500 | A Phase 2, Open Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 |
| 2020-12-23 | Incyte Corporation | St. Lukes Hospital | $1,500 | A Phase 2, Open Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 |
| 2020-12-23 | Incyte Corporation | St. Lukes Hospital | $1,000 | A Phase 2, Open Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 |
| 2020-12-16 | Celgene Corporation | St. Lukes Hospital | $1,500 | Celgene - Connect MDS/AML | 2020 |
| 2020-12-15 | Celgene Corporation | ALTA BATES SUMMIT MEDICAL CENTER | $182 | A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single | 2020 |
| 2020-07-03 | Celgene Corporation | Research & Education Institute Of Alta Bates Summit Med Cen | $500 | A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single | 2020 |
| 2020-02-17 | Celgene Corporation | SUTTER SANTA ROSA REGIONAL HOSPITAL | $3,375 | Celgene - Connect MDS/AML | 2020 |
| 2020-02-14 | Celgene Corporation | Alta Bates Summit Medical Center Brachytherapy Center | $182 | A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single | 2020 |
| 2020-02-11 | Celgene Corporation | Alta Bates Summit Medical Center Summit Campus | $1,145 | Celgene - Connect MM | 2020 |
| 2020-01-21 | E.R. Squibb & Sons, L.L.C. | ALTA BATES SUMMIT MEDICAL CENTER | $900 | A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previo | 2020 |
| 2019-11-11 | Incyte Corporation | CALIFORNIA PACIFIC MEDICAL CENTER | $8,500 | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With | 2019 |
| 2019-10-15 | Celgene Corporation | ALTA BATES SUMMIT MEDICAL CENTER | $750 | Connect MM- The Multiple Myeloma Disease Registry (OS002982) | 2019 |
| 2019-10-01 | Celgene Corporation | SUTTER EAST BAY HOSPITALS | $1,500 | Connect MM- The Multiple Myeloma Disease Registry (OS002982) | 2019 |
| 2019-09-06 | Celgene Corporation | SUTTER BAY HOSPITALS DBAJordan Research and Education | $1,326 | A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single | 2019 |
| 2019-08-08 | Incyte Corporation | ALTA BATES MED CTR | $31 | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With | 2019 |
| 2019-08-08 | Incyte Corporation | ALTA BATES MED CTR | $0 | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With | 2019 |
| 2019-08-08 | Incyte Corporation | ALTA BATES MED CTR | $58 | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With | 2019 |
| 2019-08-08 | Incyte Corporation | ALTA BATES MED CTR | $76 | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With | 2019 |
| 2019-08-08 | Incyte Corporation | ALTA BATES MED CTR | $3 | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With | 2019 |
| 2019-08-08 | Incyte Corporation | ALTA BATES MED CTR | $76 | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With | 2019 |
| 2019-08-08 | Incyte Corporation | ALTA BATES MED CTR | $76 | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With | 2019 |
| 2019-08-08 | Incyte Corporation | ALTA BATES MED CTR | $47 | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With | 2019 |
| 2019-08-08 | Incyte Corporation | ALTA BATES MED CTR | $30 | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With | 2019 |
| 2019-08-08 | Incyte Corporation | ALTA BATES MED CTR | $20 | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With | 2019 |
| 2019-08-08 | Incyte Corporation | ALTA BATES MED CTR | $40 | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With | 2019 |
| 2019-08-08 | Incyte Corporation | ALTA BATES MED CTR | $5 | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With | 2019 |
| 2019-08-08 | Incyte Corporation | ALTA BATES MED CTR | $3 | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With | 2019 |
| 2019-08-08 | Incyte Corporation | ALTA BATES MED CTR | $6 | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With | 2019 |
| 2019-08-08 | Incyte Corporation | ALTA BATES MED CTR | $6 | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With | 2019 |
| 2019-08-08 | Incyte Corporation | ALTA BATES MED CTR | $2 | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With | 2019 |
| 2019-08-08 | Incyte Corporation | ALTA BATES MED CTR | $47 | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With | 2019 |
| 2019-08-08 | Incyte Corporation | ALTA BATES MED CTR | $36 | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With | 2019 |
| 2019-07-23 | E.R. Squibb & Sons, L.L.C. | ALTA BATES SUMMIT MEDICAL CENTER | $3,888 | A Phase 3, Randomized, Open Label Trial of LenalidomideDexamethasone With or Without Elotuzumab in Subjects With Previou | 2019 |
| 2019-05-29 | Celgene Corporation | ALTA BATES SUMMIT MEDICAL CENTER | $750 | Celgene - Connect MM | 2019 |
| 2019-02-22 | Celgene Corporation | SUTTER SANTA ROSA REGIONAL HOSPITAL | $3,375 | Celgene - Connect MDSAML | 2019 |
| 2019-01-02 | Celgene Corporation | ALTA BATES SUMMIT MEDICAL CENTER | $750 | Celgene - Connect CLL | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Berkeley, CA, county Alameda County, CA, state California; placed by its city name.
| Measure | Place (city or town) Berkeley, CA | County Alameda County, CA | State California |
|---|---|---|---|
| Population B01003 | 120,257 | 1,649,473 | 39,287,377 |
| Population, 2020 census P1 | 124,321 | 1,682,353 | 39,538,223 |
| Median age B01002 | 33.2 | 39.0 | 37.9 |
| Under 18 B01001 | 12.7% | 19.8% | 22.0% |
| 65 and over B01001 | 16.7% | 15.4% | 15.7% |
| Households B11001 | 47,135 | 598,246 | 13,548,091 |
| Foreign born B05002 | 21.1% | 34.7% | 27.0% |
| Median household income B19013 | $108,092 | $129,367 | $99,122 |
| Median family income B19113 | $202,712 | $159,585 | $113,346 |
| Per capita income B19301 | $69,534 | $65,862 | $49,513 |
| Poverty rate B17001 | 17.3% | 9.2% | 12.0% |
| Unemployment rate B23025 | 5.6% | 5.4% | 6.6% |
| Civilian labor force B23025 | 64,277 | 908,995 | 20,068,466 |
| Mean commute (minutes) B08013 | 27.8 | 31.0 | 28.7 |
| Bachelor's degree or higher B15003 | 74.9% | 52.2% | 37.1% |
| Housing units B25001 | 53,145 | 637,212 | 14,644,735 |
| Owner-occupied B25003 | 44.2% | 54.4% | 55.9% |
| Renters B25003 | 55.8% | 45.6% | 44.1% |
| Median home value B25077 | $1,413,900 | $1,090,100 | $734,700 |
| Median gross rent B25064 | $2,133 | $2,357 | $2,036 |
| White, not Hispanic B03002 | 49.9% | 27.4% | 33.8% |
| Black B03002 | 7.7% | 9.3% | 5.2% |
| Hispanic or Latino B03002 | 12.8% | 23.4% | 40.2% |
| Asian B03002 | 20.4% | 32.7% | 15.3% |
| American Indian and Alaska Native B03002 | 0.1% | 0.2% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Berkeley, CA.
Comments